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2 Chronic hepatitis C virus (HCV) infection is a leading cause of liver-related morbidity and mortality worldwide [1] . In addition, chronic HCV infection is considered a systemic infection with many extrahepatic manifestations that can lead to poor quality of life and major economic burden [2, 3] . Evidence of associations with stroke, coronary artery disease, peripheral arterial disease and heart failure suggested that HCV infection might be a new cardiovascular (CV) risk factor [4] . Patients with HCV infection frequently have CV-associated risk factors such as diabetes, chronic kidney disease or hypertension.
However, it should be underlined that -as for all diseases or events -risk factors are rigorously defined by four types of evidence: (1) observational studies showing the presence of the factor before the event appearance; (2) prospective translational or clinical studies demonstrating an increased prevalence rate of the factor in patients who will develop the event; (3) mechanism of action studies; and (4) most importantly, outcome studies showing risk reduction when the putative factor is corrected. The study by Butt et al [5] adds major information in this field. From a large cohort of HCV-infected Veterans, they found direct acting agent (DAA) treatment was associated with a 43% reduction and pegylated interfon plus ribavirin (pegIFN/RBV) with a 22% reduction in risk of incident CV events compared with no treatment. Treatment with a DAAs was associated with lower event rates for all CV event compared with non-treated controls and those treated with a pegIFN/RBV. This publication was the missing part of the puzzle which now sustains the following assertion, the "factor" (HCV infection) is a new reversible independent risk factor for CV disease ("the event").
Clinical studies demonstrated increased prevalence rate of HCV infection in patients who develop a major cardiovascular event
A meta-analysis (total N=68,365) showed an association between HCV infection and CV death (odds ratio 1.65; 95%CI 1.07-2.56) [6] . The risk of carotid plaques and carotid intima-media thickness was two-fold higher in HCV-infected individuals compared with uninfected controls [6] . Individuals with HCV infection compared with HCV-negative controls have increased incidence of stroke. Conversely, a higher prevalence of HCV infection have been found in patients with stroke than in age-and sex-matched controls [7] . In a cohort of 150,000 patients (82,082 of whom were HCV-positive), the prevalence of HCV infection was higher in patients with stable coronary artery disease (CAD) than in patients without CAD after adjusting for confounding factors [8] . In large prospective cohorts, HCV-infected patients had a higher incidence at a younger age of acute myocardial infarction than HCV-negative men [9] . HCV seropositivity was associated with cardiac dysfunction and increased risk of heart failure when compared with seronegative individuals [4] .
Mechanism of action studies
There are many potential direct and indirect mechanisms by which HCV could increase CV risk [4, 10] . The insulin resistance associated with HCV leads to hyperglycemia, steatosis, endothelial dysfunction and low grade systemic inflammation all of which produce vessel damage and unstable plaques [7, 11] . Non-obese, non-diabetic, treatment-naïve HCV infected patients have higher pro-inflammatory cytokine levels than blood donors [12] . The presence of HCV has been correlated with higher levels of inflammatory markers in patients with stroke [7] . Biomarkers predictive of CAD were more elevated in HCV-infected patients than among controls, i.e. high-sensitivity Creactive protein, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1 and soluble E-selectin [13] . The incidence of CV events was higher in patients M A N U S C R I P T
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4 with detectable HCV RNA levels and the risk of cerebrovascular death has been correlated with HCV RNA levels [9, 14] . The virus has been shown to infect the brain endothelial cells [15] . Positive-strand HCV RNA was detected in carotid plaque tissues from HCV-positive patients and not in carotid plaque from HCV-negative patients [16] . HCV RNA has been found in myocardial tissue of patients with hypertrophic cardiomyopathy and those with dilated cardiomyopathy. In a large cohort of HCV-infected patients, Butt et al [5] analysed treated patients (pegIFN/RBV, or DAA) matched for age, race, sex, and baseline values with patients who had never received treatment. The rate of incident CV events was lower in the treated vs.
the control group (7.2% vs. 13.8%). A SVR was associated with a 13% lower risk of incident CV events.
To summarize, the availability of safe and effective antiviral regimens that eradicate HCV infection in most patients, together with evidence that HCV infection is a reversible CV risk factor, reinforce some practical messages: (1) all HCV infected patients should have access to DAAs; (2) all HCV infected patients should benefit of a complete CV check-up; (3) liver, and more importantly non-liver physician should be aware of the benefit of DAA to improve liver and cardiovascular outcomes. 
